Hantz Financial Services’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Hantz Financial Services’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100	Closed	-$9.69K	–	1218
2024 Q3	$10K	Hold	100	–	–	﹤0.01%	797
2024 Q2	$9K	Sell	100 -23	-19%	-$2.06K	﹤0.01%	811
2024 Q1	$12K	Buy	123 +60	+95%	+$5.57K	﹤0.01%	813
2023 Q4	$6K	Buy	63 +60	+2,000%	+$4.46K	﹤0.01%	895
2023 Q3	$0	Hold	3	–	–	﹤0.01%	1197
2023 Q2	$0	Hold	3	–	–	﹤0.01%	1188
2023 Q1	$0	Hold	3	–	–	﹤0.01%	1211
2022 Q4	$0	Hold	3	–	–	﹤0.01%	1167
2022 Q3	$0	Buy	+3	New	+$253	﹤0.01%	1147

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Hantz Financial Services's XBI Position: Q4 2024 in Review

Hantz Financial Services sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 100 shares — an estimated $9.69K sold.

Hantz Financial Services first reported a position in XBI in Q3 2022 and held it in 9 quarters. The position peaked at $12K in Q1 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

Hantz Financial Services reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
Hantz Financial Services sold 100 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $9.69K.
Hantz Financial Services first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and held it in 9 quarters.
Hantz Financial Services's State Street SPDR S&P Biotech ETF position peaked at $12K in Q1 2024.
738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Hantz Financial Services's 13F filing for Q4 2024, filed 23 Jan 2025.